Study · Not a test of the peptide alone · 2025

13 results

Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.

Shah VN, Agesen RM, Bardtrum L, Christiansen E, Snaith J, Greenfield JR

Journal of diabetes science and technology24 Dec 2024Cited by 8 (Europe PMC)

PMID39717993PMCIDPMC11669135DOI10.1177/19322968241305647PepBankPUB-39717993

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone13

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyOther
In T1D participants receiving liraglutide with background insulin, baseline type 1 diabetes duration differed between completers and non-completers in post hoc analyses; direction was unspecified.
In plain wordsIn T1D liraglutide participants, starting type 1 diabetes duration differed between treatment completers and non-completers; direction was unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedType 1 diabetes duration at baseline
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Endocrine and hormones
Source sentences
Summary
When analyzed by treatment group, only duration of T1D and C-peptide differed between completers and non-completers among liraglutide (and not placebo) participants.
2 context sentences(design, population, supporting numbers)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799301
02HumanNot a test of Liraglutide aloneObservational studyOther
In T1D participants receiving liraglutide with background insulin, baseline C-peptide differed between completers and non-completers in post hoc analyses; direction was unspecified.
In plain wordsIn T1D liraglutide participants, starting C-peptide differed between treatment completers and non-completers; direction was unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedC-peptide at baseline
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Endocrine and hormones
Source sentences
Summary
When analyzed by treatment group, only duration of T1D and C-peptide differed between completers and non-completers among liraglutide (and not placebo) participants.
2 context sentences(design, population, supporting numbers)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799302
03HumanNot a test of Liraglutide aloneObservational studyOther
In ADJUNCT ONE T1D participants pooled across liraglutide/placebo, non-completers had lower baseline body mass index than completers (27.8 versus 29.8 kg/m2; P < .0001).
In plain wordsIn ADJUNCT ONE T1D participants, pooled liraglutide/placebo non-completers had lower starting body mass index than completers.
Peptide
Liraglutide
Outcome
DecreaseBaseline body mass index in ADJUNCT ONE
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Metabolic and weight
Measurements
Body mass index
27.8 kg/m2
non-completers; P < .0001 versus completers
Body mass index
29.8 kg/m2
completers
Source sentences
Summary
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI) (ADJUNCT ONE: 27.8 kg/m² vs 29.8 kg/m², P < .0001;
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799303
04HumanNot a test of Liraglutide aloneObservational studyOther
In ADJUNCT ONE T1D participants pooled across liraglutide/placebo, non-completers had higher baseline type1 diabetes duration than completers (25.8 versus 21.0 years; P < .0001).
In plain wordsIn ADJUNCT ONE T1D participants, pooled liraglutide/placebo non-completers had higher starting type 1 diabetes duration than completers.
Peptide
Liraglutide
Outcome
IncreaseBaseline type1 diabetes duration in ADJUNCT ONE
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Endocrine and hormones
Measurements
Type1 diabetes duration
25.8 years
non-completers; P < .0001 versus completers
Type1 diabetes duration
21 years
completers
Source sentences
Summary
longer duration of T1D (25.8 years vs 21.0 years, P < .0001;
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799304
05HumanNot a test of Liraglutide aloneObservational studyOther
In ADJUNCT ONE T1D participants pooled across liraglutide/placebo, non-completers had lower baseline daily continuous-infusion insulin dose than completers (46.4 versus 57.3 U; P = .01).
In plain wordsIn ADJUNCT ONE T1D participants, pooled liraglutide/placebo non-completers had lower starting daily continuous-infusion insulin dose than completers.
Peptide
Liraglutide
Outcome
DecreaseBaseline daily continuous-infusion insulin dose in ADJUNCT ONE
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Endocrine and hormones
Measurements
Daily continuous-infusion insulin dose
46.4 U
non-completers; P = .01 versus completers
Daily continuous-infusion insulin dose
57.3 U
completers
Source sentences
Summary
lower daily insulin doses by continuous infusion (46.4 U vs 57.3 U, P = .01;
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799305
06HumanNot a test of Liraglutide aloneObservational studyOther
In ADJUNCT ONE T1D participants pooled across liraglutide/placebo, non-completers had lower baseline daily multiple-injection insulin dose than completers (58.4 versus 68.5 U; P = .006).
In plain wordsIn ADJUNCT ONE T1D participants, pooled liraglutide/placebo non-completers had lower starting daily multiple-injection insulin dose than completers.
Peptide
Liraglutide
Outcome
DecreaseBaseline daily multiple-injection insulin dose in ADJUNCT ONE
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Endocrine and hormones
Measurements
Daily multiple-injection insulin dose
58.4 U
non-completers; P = .006 versus completers
Daily multiple-injection insulin dose
68.5 U
completers
Source sentences
Summary
or multiple injections (58.4 U vs 68.5 U, P = .006;
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799306
07HumanNot a test of Liraglutide aloneObservational studyOther
In ADJUNCT ONE T1D participants pooled across liraglutide/placebo, non-completers more often had undetectable baseline C-peptide than completers (91.5% versus 81.3%; statistical test unspecified).
In plain wordsIn ADJUNCT ONE T1D participants pooled across liraglutide/placebo, non-completers more often had undetectable starting C-peptide than completers.
Peptide
Liraglutide
Outcome
IncreaseProportion with undetectable baseline C-peptide in ADJUNCT ONE
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Endocrine and hormones
Measurements
Undetectable baseline C-peptide
91.5%
non-completers; test unspecified
Undetectable baseline C-peptide
81.3%
completers
Source sentences
Summary
and a higher proportion of participants with undetectable C-peptide (91.5% vs 81.3%;
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799307
08HumanNot a test of Liraglutide aloneObservational studySafety outcome
In T1D participants pooled across liraglutide and placebo in post hoc ADJUNCT analyses, adverse-event rates were higher in non-completers than completers.
In plain wordsIn pooled T1D liraglutide/placebo participants, non-completers had higher side-effect rates than completers.
Peptide
Liraglutide
Outcome
IncreaseAdverse event rates
Study
n: not reported in source
Comparator
Completers
Outcome group
Adverse events · Whole body
Source sentences
Summary
The AE rates were higher for non-completers.
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799308
09HumanNot a test of Liraglutide aloneObservational studyOther
In ADJUNCT TWO T1D participants pooled across liraglutide/placebo, non-completers had lower baseline body mass index than completers (26.3 versus 29.2 kg/m2; P < .0001).
In plain wordsIn ADJUNCT TWO T1D participants, pooled liraglutide/placebo non-completers had lower starting body mass index than completers.
Peptide
Liraglutide
Outcome
DecreaseBaseline body mass index in ADJUNCT TWO
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Metabolic and weight
Measurements
Body mass index
26.3 kg/m2
non-completers; P < .0001 versus completers
Body mass index
29.2 kg/m2
completers
Source sentences
Summary
ADJUNCT TWO: 26.3 kg/m² vs 29.2 kg/m², P < .0001),
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799309
10HumanNot a test of Liraglutide aloneObservational studyOther
In ADJUNCT TWO T1D participants pooled across liraglutide/placebo, non-completers had higher baseline type1 diabetes duration than completers (24.1 versus 21.0 years; P = .04).
In plain wordsIn ADJUNCT TWO T1D participants, pooled liraglutide/placebo non-completers had higher starting type 1 diabetes duration than completers.
Peptide
Liraglutide
Outcome
IncreaseBaseline type1 diabetes duration in ADJUNCT TWO
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Endocrine and hormones
Measurements
Type1 diabetes duration
24.1 years
non-completers; P = .04 versus completers
Type1 diabetes duration
21 years
completers
Source sentences
Summary
24.1 years vs 21.0 years, P = .04)
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799310
11HumanNot a test of Liraglutide aloneObservational studyOther
In ADJUNCT TWO T1D participants pooled across liraglutide/placebo, non-completers had lower baseline daily continuous-infusion insulin dose than completers (40.9 versus 57.4 U; P = .12, not statistically significant).
In plain wordsIn ADJUNCT TWO T1D participants, pooled liraglutide/placebo non-completers had lower starting daily continuous-infusion insulin dose than completers.
Peptide
Liraglutide
Outcome
DecreaseBaseline daily continuous-infusion insulin dose in ADJUNCT TWO
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Endocrine and hormones
Measurements
Daily continuous-infusion insulin dose
40.9 U
non-completers; P = .12 versus completers
Daily continuous-infusion insulin dose
57.4 U
completers
Source sentences
Summary
40.9 U vs 57.4 U, P = .12)
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799311
12HumanNot a test of Liraglutide aloneObservational studyOther
In ADJUNCT TWO T1D participants pooled across liraglutide/placebo, non-completers had lower baseline daily multiple-injection insulin dose than completers (56.0 versus 65.8 U; P = .03).
In plain wordsIn ADJUNCT TWO T1D participants, pooled liraglutide/placebo non-completers had lower starting daily multiple-injection insulin dose than completers.
Peptide
Liraglutide
Outcome
DecreaseBaseline daily multiple-injection insulin dose in ADJUNCT TWO
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Endocrine and hormones
Measurements
Daily multiple-injection insulin dose
56 U
non-completers; P = .03 versus completers
Daily multiple-injection insulin dose
65.8 U
completers
Source sentences
Summary
56.0 U vs 65.8 U, P =.03)
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799312
13HumanNot a test of Liraglutide aloneObservational studyOther
In ADJUNCT TWO T1D participants pooled across liraglutide/placebo, non-completers more often had undetectable baseline C-peptide than completers (87.0% versus 84.9%; statistical test unspecified).
In plain wordsIn ADJUNCT TWO T1D participants pooled across liraglutide/placebo, non-completers more often had undetectable starting C-peptide than completers.
Peptide
Liraglutide
Outcome
IncreaseProportion with undetectable baseline C-peptide in ADJUNCT TWO
Study
n: not reported in source
Comparator
Completers
Outcome group
Patterns of use · Endocrine and hormones
Measurements
Undetectable baseline C-peptide
87%
non-completers; test unspecified
Undetectable baseline C-peptide
84.9%
completers
Source sentences
Summary
87.0% vs 84.9%) compared to completers.
3 context sentences(design, population, supporting numbers)
Summary · context
Non-completers (liraglutide and placebo combined) had lower baseline body mass index (BMI)
Summary · context
Two phase 3 randomized controlled studies (ADJUNCT ONE (Clinicaltrials.gov: NCT01836523), ADJUNCT TWO (Clinicaltrials.gov: NCT02098395)) evaluated liraglutide (1.8, 1.2 or 0.6 mg) vs placebo in participants with type 1 diabetes (T1D) as an adjunct to insulin therapy.
Summary · context
Post hoc comparisons were conducted on baseline characteristics and adverse event (AE) rates of participants completing and not completing the ADJUNCT studies due to AEs/lack of tolerance using summary tables and variance analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3971799313

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02098395

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

Novo Nordisk A/Sn = 835May 2014 to Apr 2015

Diabetes · Diabetes Mellitus, Type 1

Trial page ClinicalTrials.govUpdated 9 Feb 2017

CompletedPhase 3Results postedNCT01836523

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

Novo Nordisk A/Sn = 1,398Nov 2013 to Jun 2015

Diabetes · Diabetes Mellitus, Type 1

Trial page ClinicalTrials.govUpdated 6 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.